Reversible Audiometric Threshold Changes in Children with Uncomplicated Malaria

Figure 3

(a) Audiometry data at 9–12 months followup by treatment group. Amodiaquine (dark shaded, 𝑛=3), artemisinin-lumefantrine (light shaded, 𝑛=23), artesunate-amodiaquine (open, 𝑛=30). No difference could be shown across all wavelengths and both ears (two-way repeated measurement ANOVA on ranks 𝑃=0.7). (b) Hearing threshold on day 7 after treatment relative to threshold before treatment by group. Colours as (a). Columns and error bars as in Figure 2. Patients treated with amodiaquine alone had significant increase in hearing threshold across all wavelengths compared with patients treated with ACT, who had unchanged threshold compared to day 0 (two-way repeated measurement ANOVA on ranks 𝑃<0.001, Holm-Sidak post hoc test of amodiaquine versus artemether-lumefantrine 𝑃<0.001, of amodiaquine versus artesunate-amodiaquine 𝑃=0.003, amodiaquine 𝑛=5, artemether-lumefantrine 𝑛=21, artesunate-amodiaquine 𝑛=15).

(a)

(b)